FULCRUM THERAPEUTICS INC (FULC)
US3596161097 - Common Stock
Overall FULC gets a fundamental rating of 3 out of 10. We evaluated FULC against 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for FULC as it has an excellent financial health rating, but there are worries on the profitability. FULC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year FULC has reported negative net income.
FULC had a negative operating cash flow in the past year.
FULC had negative earnings in each of the past 5 years.
FULC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -37.77%, FULC perfoms like the industry average, outperforming 50.51% of the companies in the same industry.
Looking at the Return On Equity, with a value of -41.39%, FULC is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.77% | ||
| ROE | -41.39% | ||
| ROIC | N/A |
ROA(3y)-40.21%
ROA(5y)-51.33%
ROE(3y)-44.95%
ROE(5y)-62.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FULC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.
FULC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FULC has more shares outstanding
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
FULC has an Altman-Z score of 8.55. This indicates that FULC is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of FULC (8.55) is better than 85.71% of its industry peers.
FULC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.55 |
ROIC/WACCN/A
WACC9.23%
2.3 Liquidity
A Current Ratio of 17.71 indicates that FULC has no problem at all paying its short term obligations.
FULC has a Current ratio of 17.71. This is amongst the best in the industry. FULC outperforms 92.86% of its industry peers.
FULC has a Quick Ratio of 17.71. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.
FULC has a better Quick ratio (17.71) than 92.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.71 | ||
| Quick Ratio | 17.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.29% over the past year.
Looking at the last year, FULC shows a very negative growth in Revenue. The Revenue has decreased by -55.66% in the last year.
Measured over the past years, FULC shows a very negative growth in Revenue. The Revenue has been decreasing by -31.74% on average per year.
EPS 1Y (TTM)36.29%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q20%
Revenue 1Y (TTM)-55.66%
Revenue growth 3Y-31.74%
Revenue growth 5YN/A
Revenue growth Q2Q26.23%
3.2 Future
The Earnings Per Share is expected to grow by 18.42% on average over the next years. This is quite good.
Based on estimates for the next years, FULC will show a very strong growth in Revenue. The Revenue will grow by 147.69% on average per year.
EPS Next Y-12.73%
EPS Next 2Y-4.99%
EPS Next 3Y7.89%
EPS Next 5Y18.42%
Revenue Next Year-17.34%
Revenue Next 2Y139.83%
Revenue Next 3Y203.61%
Revenue Next 5Y147.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
FULC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FULC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.99%
EPS Next 3Y7.89%
5. Dividend
5.1 Amount
FULC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FULCRUM THERAPEUTICS INC
NASDAQ:FULC (4/19/2024, 1:43:30 PM)
6.72
-0.34 (-4.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap416.24M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.77% | ||
| ROE | -41.39% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 17.71 | ||
| Quick Ratio | 17.71 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)36.29%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-12.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-55.66%
Revenue growth 3Y-31.74%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y